TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00489203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given after transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Given after transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given after transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given after transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo stem cell transplant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo stem cell transplant
Study: NCT02317237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Description: Conscious sedation
Study: NCT02805322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC InstaTemp MD
Description: Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien Genius 2 Tympanic Thermometer
Description: Measurement of Tympanic Temperature using a standard approved method - Control arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Welch Allen SureTemp Plus Sublingual Thermometer
Description: Measurement of Sublingual Temperature using a standard approved method - Control arm.
Study: NCT03807141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Description: This is a modified version of the ketogenic diet where-in carbohydrates are restricted without any protein or calorie restriction.
Study: NCT03113006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation
Description: Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation
Description: Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
Study: NCT00148564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: treatment with either Olanzapine or Ziprasidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: treatment with either Olanzapine or Ziprasidone
Study: NCT03980288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T Cells
Description: Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
Study: NCT02995070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG
Description: Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: CTG
Description: Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: Low Level Laser Therapy on the buccal recipient site of connective tissue graft.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
Study: NCT00290147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Description: IM injection delivered by Biojector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Description: IM injection delivered by Biojector
Study: NCT01806090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)
Study: NCT00076102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m\^2 every 8 hours (1500 mg/m2/day).
Study: NCT00582088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEE C-84
Description: Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer \<1:20.
Study: NCT02854280

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedalling exercise on a cycle ergometer
Description: At 80% of the maximal aerobic power, until exhaustion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedalling exercise on a cycle ergometer
Description: At 80% of the maximal aerobic power, until exhaustion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedalling exercise on a cycle ergometer
Description: At 80% of the maximal aerobic power, until exhaustion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Isolated contractions of the quadriceps
Description: Until exhaustion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Isolated contractions of the quadriceps
Description: Until exhaustion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Isolated contractions of the quadriceps
Description: Until exhaustion
Study: NCT02679183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically-Graded Honey
Description: Honey added to the baby formula once a day for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically-Graded Honey
Description: Honey added to the baby formula once a day for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically-Graded Honey
Description: Honey added to the baby formula once a day for 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Premature Milk Formula
Description: Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premature Milk Formula
Description: Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premature Milk Formula
Description: Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premature Milk Formula
Description: Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
Study: NCT03414749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower Extremity First (LEF)
Description: The intervention for the LEF group was a non-specific long-axis distraction to the ankle, knee, and hip or shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Extremity First (UEF)
Description: The intervention for the UEF group was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
Study: NCT02635243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR438544
Description: Pharmaceutical form:solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR438544
Description: Pharmaceutical form:solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-glucagon
Description: Pharmaceutical form:solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT03931642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCHOP
Description: D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab by continuous vein infusion
Study: NCT02608502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Placebo
Study: NCT00401778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD001
Description: Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD001
Description: Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
Study: NCT01536626

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Prescription at the discretion of the treating physician
Study: NCT02930005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclofenamic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium
Study: NCT01001208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate tablets over-encapsulated for blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 1 mL for subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 1 mL for subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to methotrexate capsules
Study: NCT01780415

Intervention type: OTHER
Intervention: blastocoele aspiration
Study: NCT01767064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posted commitment letter
Study: NCT03319420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LO2A eye drops
Description: Sodium hyaluronate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra UD
Description: Active Ingredients; Polyethylene Glycol Propylene Glycol
Study: NCT03250533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diodes (LED)
Description: The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diodes (LED)
Description: The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed diphasic current
Description: The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
Study: NCT01265784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered IV to maintain the blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV to maintain the blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV to maintain the blind.
Study: NCT00421005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvastatin
Description: Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvastatin
Description: Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
Study: NCT00883090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FXIII Concentrate (Human)
Description: Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
Study: NCT04362397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FoCo
Description: This is an attention, care and self-care training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FoCo
Description: This is an attention, care and self-care training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: This is a waiting list

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: This is a waiting list
Study: NCT01779323

Intervention type: OTHER
Intervention: Pre and Post Sling Pelvic MRI
Description: Pre and Post Sling Pelvic MRI
Study: NCT01333527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Sling
Description: Early range of motion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sling
Description: Patients will use the sling for 6 weeks, as per usual care
Study: NCT02304432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCS or placebo
Description: Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
Study: NCT04453202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of placebo on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of placebo on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single IM injection of placebo on Day 1.
Study: NCT03031054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection with hyaluronic acid
Description: Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sono-guided injection with normal saline
Description: Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
Study: NCT01400425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose
Study: NCT00235456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative supplemental oxygen
Description: Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard oxygen
Description: Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
Study: NCT03811080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 A mg
Description: The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 B mg
Description: The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
Study: NCT03394209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75Mg Capsule
Description: oseltamivir will be administered at 75mg twice daily orally for 10 days
Study: NCT03536624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 days spa residential program
Description: 6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
Study: NCT03231956

Intervention type: DEVICE
Intervention: ClearSight™ / EV1000NI Clinical Platform
Description: Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System

Intervention type: DEVICE
Intervention: ClearSight™ / EV1000NI Clinical Platform
Description: Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System

Intervention type: DEVICE
Intervention: ClearSight™ / EV1000NI Clinical Platform
Description: Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System

Intervention type: DEVICE
Intervention: ClearSight™ / EV1000NI Clinical Platform
Description: Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System